BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 7718516)

  • 1. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.
    Rowan WC; Hale G; Tite JP; Brett SJ
    Int Immunol; 1995 Jan; 7(1):69-77. PubMed ID: 7718516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
    Hederer RA; Guntermann C; Miller N; Nagy P; Szollosi J; Damjanovich S; Hale G; Alexander DR
    Int Immunol; 2000 Apr; 12(4):505-16. PubMed ID: 10744652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
    Rowan W; Tite J; Topley P; Brett SJ
    Immunology; 1998 Nov; 95(3):427-36. PubMed ID: 9824507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
    Brett SJ; Baxter G; Cooper H; Rowan W; Regan T; Tite J; Rapson N
    Int Immunol; 1996 Mar; 8(3):325-34. PubMed ID: 8671618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H.
    Brett S; Baxter G; Cooper H; Johnston JM; Tite J; Rapson N
    Immunology; 1996 May; 88(1):13-9. PubMed ID: 8707338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A co-stimulatory role for CD28 in the activation of CD4+ T lymphocytes by staphylococcal enterotoxin B.
    Goldbach-Mansky R; King PD; Taylor AP; Dupont B
    Int Immunol; 1992 Dec; 4(12):1351-60. PubMed ID: 1363054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
    Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
    Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human resting B lymphocytes can serve as accessory cells for anti-CD2-induced T cell activation.
    Hirokawa M; Gray JD; Takahashi T; Horwitz DA
    J Immunol; 1992 Sep; 149(6):1859-66. PubMed ID: 1355500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation.
    de Waal Malefyt R; Yssel H; de Vries JE
    J Immunol; 1993 Jun; 150(11):4754-65. PubMed ID: 7684412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.
    Shah A; Lowenstein H; Chant A; Khan A
    Transpl Int; 2006 Sep; 19(9):749-58. PubMed ID: 16918536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functionally anergic lpr and gld B220+ T cell receptor (TCR)-alpha/beta+ double-negative T cells express CD28 and respond to costimulation with phorbol myristate acetate and antibodies to CD28 and the TCR.
    Giese T; Allison JP; Davidson WF
    J Immunol; 1993 Jul; 151(2):597-609. PubMed ID: 7687618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.
    Taylor VC; Sims M; Brett S; Field MC
    Biochem J; 1997 Mar; 322 ( Pt 3)(Pt 3):919-25. PubMed ID: 9148769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
    Watanabe T; Masuyama J; Sohma Y; Inazawa H; Horie K; Kojima K; Uemura Y; Aoki Y; Kaga S; Minota S; Tanaka T; Yamaguchi Y; Kobayashi T; Serizawa I
    Clin Immunol; 2006 Sep; 120(3):247-59. PubMed ID: 16797237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
    von Kutzleben S; Pryce G; Giovannoni G; Baker D
    Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
    Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The distribution of the CDW52 molecule on blood cells and characterization of its involvement in T cell activation.
    Valentin H; Gelin C; Coulombel L; Zoccola D; Morizet J; Bernard A
    Transplantation; 1992 Jul; 54(1):97-104. PubMed ID: 1352921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A; Stevenson GT; Glennie MJ
    J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purified human T cells stimulated with cross-linked anti-CD3 monoclonal antibody OKT3: rIL-1 is a co-stimulatory factor for CD4+CD29+CD45RA- T cells.
    Panzer S; Geller RL; Bach FH
    Scand J Immunol; 1990 Oct; 32(4):359-71. PubMed ID: 1700468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.